Seattle Children's Launches Groundbreaking Gene Therapy Trial for Congenital Deafness, Led by Rubinstein

Seattle Children's has recently finalized a clinical trial agreement with Decibel Therapeutics to pioneer gene therapy for children affected by deafness due to otoferlin mutations. This marks the inaugural use of gene therapy for congenital deafness. Jay Rubinstein, MD, PhD, a professor at UW Oto, serves as the local/regional Principal Investigator for this international clinical trial, addressing the rarity of the mutation. Seattle Children's proudly becomes the first US site to formalize this significant contract, and they are currently in the active recruitment phase for potential subjects.